Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CX-516 (Cortex Pharmaceuticals Inc).

W Danysz1

  • 1Merz & Co, Department of Pharmacological Research, Eckenheimer Landstrasse 100-104, 60318 Frankfurt/Main, Germany. wdanysz@t-online.de

Idrugs : the Investigational Drugs Journal
|August 30, 2005
PubMed
Summary

CX-516, an AMPA modulator, shows promise in treating cognitive deficits in Alzheimer's disease and improving cognitive function in schizophrenia patients. Further research is exploring its antidepressant and antipsychotic potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma.

Neurotoxicity research·2014
Same author

The dopamine reuptake inhibitor MRZ-9547 increases progressive ratio responding in rats.

The international journal of neuropsychopharmacology·2014
Same author

Glutamate, learning and dementia-selection of evidence.

Amino acids·2013
Same author

On the role of NMDA receptors in blood pressure regulation in spontaneously hypertensive rats (SHR).

Amino acids·2013
Same author

Microdialysate analysis of monoamine neurotransmitters--a versatile and sensitive LC-MS/MS method.

Analytica chimica acta·2013
Same author

Interaction of blockers of ionotropic NMDA receptors and metabotropic glutamate receptors in a working memory test in rats.

Neuroscience and behavioral physiology·2010

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • CX-516 is an AMPA modulator developed by Cortex Pharmaceuticals.
  • AMPA modulators, also known as AMPAkines, are being investigated for various neurological and psychiatric conditions.
  • Cortex Pharmaceuticals has licensed AMPAkine technology to Organon for schizophrenia and depression treatments.

Purpose of the Study:

  • To evaluate CX-516 for the symptomatic treatment of memory and cognition deficits in Alzheimer's disease (AD).
  • To investigate the potential antidepressant and antipsychotic activities of CX-516 and related AMPAkines.
  • To assess the efficacy of CX-516 in combination with clozapine for schizophrenia patients.

Main Methods:

  • Phase I/IIa clinical trials for Alzheimer's disease.
  • Preclinical studies investigating antidepressant and antipsychotic activities.
  • Clinical trial in schizophrenia patients combining CX-516 with clozapine.

Main Results:

  • CX-516 is in clinical trials for Alzheimer's disease.
  • CX-691 and CX-519 demonstrated antidepressant activities in initial studies.
  • CX-516 improved cognitive functions in schizophrenia patients when used with clozapine.

Conclusions:

  • CX-516 shows potential for treating cognitive deficits in Alzheimer's disease.
  • AMPAkines, including CX-516, exhibit potential antidepressant and antipsychotic effects.
  • CX-516 may improve cognitive function in schizophrenia patients.

Related Experiment Videos